Experience

Davis Polk advised the sole book-running manager in connection with an offering by The Bank of N.T. Butterfield & Son Limited of $100 million aggregate principal amount of its 5.250%…

Davis Polk advised the underwriters on an SEC-registered offering by BankUnited, Inc. of $300 million aggregate principal amount of 5.125% subordinated notes due 2030.BankUnited, Inc…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on an SEC-registered offering by Hormel Foods Corporation of $1 billion aggregate…

Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $850 million aggregate…

Davis Polk advised the underwriters in the secondary listing and initial public offering of NetEase, Inc. on the Hong Kong Stock Exchange. The gross proceeds from the global offering…

Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…

Davis Polk advised the representatives of the several initial purchasers in connection with the offering by Seagate HDD Cayman of $500 million aggregate principal amount of its 4.125%…

Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend Biotech Corporation of 21,188,750 American Depositary Shares, each…

Davis Polk advised Clarivate Plc in connection with the $1.08 billion SEC-registered offering of 48,000,000 of its ordinary shares, of which 14,000,000 ordinary shares were issued and sold…

Davis Polk advised the representatives of the initial purchasers in a Rule 144A/Regulation S offering by Macy’s, Inc. of $1.3 billion aggregate principal amount of its 8.375% senior…